Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma (Skin), Pancreatic Cancer
Conditions
Keywords
stage IV melanoma, recurrent melanoma, stage IV non-small cell lung cancer, recurrent non-small cell lung cancer, extensive stage small cell lung cancer, recurrent small cell lung cancer, stage IV breast cancer, recurrent breast cancer, male breast cancer, stage III pancreatic cancer, stage IV pancreatic cancer, recurrent pancreatic cancer, stage IV colon cancer, recurrent colon cancer, stage IV rectal cancer, recurrent rectal cancer
Brief summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in peptides and proteins and identify biomarkers related to cancer. PURPOSE: This research study is looking at blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.
Detailed description
OBJECTIVES: Primary * To assess which potential peptide and protein markers produced by human melanoma, lung, breast, pancreatic, and colorectal cell lines may be detectable in serum of patients from these five disease groups. Secondary * To conduct further extensive investigation with respect to identification of the protein/peptide involved, determination of specificity for each cancer, and development of more sensitive assays to look for such markers in a wider population of patients, including those undergoing therapy. OUTLINE: This is a multicenter study. Blood samples are collected before surgical intervention or treatment to assess peptide and protein markers.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following advanced metastatic malignancies: * Malignant melanoma * Lung cancer * Breast cancer * Pancreatic carcinoma * Colorectal cancer * Advanced and/or metastatic disease * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Menopausal status not specified PRIOR CONCURRENT THERAPY: * Not specified
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Detection of peptide and protein markers in serum | Ongoing |
Secondary
| Measure | Time frame |
|---|---|
| Identification of the protein/peptide involved | Ongoing |
Countries
Ireland